Breaking Stories

: Biogen’s pivotal moment: Will the FDA approve the experimental — and controversial — Alzheimer’s-disease drug aducanumab?


U.S. regulators are expected to decide whether to approve Biogen’s experimental Alzheimer’s disease drug sometime this week, a decision that could send the company’s stock price soaring or tumbling depending on the outcome.

Europe Markets: European stocks edge back from record high as key U.S. report looms

Previous article

Economic Report: U.S. gains 978,000 private sector jobs in May, ADP says

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *